Tubers and tumors: rapamycin therapy for benign and malignant tumors

Current Opinion in Cell Biology

Volumn 21, Issue 2, 2009, Pages 230-236

  Plas, David R ^a   Thomas, George ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFOROLIMUS; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; RAPAMYCIN; RHEB PROTEIN; TEMSIROLIMUS;

APOPTOSIS; CARDIOVASCULAR DISEASE; CELL METABOLISM; CLINICAL TRIAL; HAMARTOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CANCER; KIDNEY CARCINOMA; PHAKOMATOSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMINO ACIDS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; NEUROCUTANEOUS SYNDROMES; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION FACTORS;

EID: 63849192586     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ceb.2008.12.013     Document Type: Review

References (63)

1. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., and Sabatini D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14 (2004) 1296-1302
2. Dan H.C., Sun M., Yang L., Feldman R.I., Sui X.M., Yeung R.S., Halley D.J., Nicosia S.V., Pledger W.J., and Cheng J.Q. PI3K/AKT pathway regulates TSC tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 11 (2002) 11
3. Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4 (2002) 648-657
4. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., and Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10 (2002) 151-162
5. Nellist M., Goedbloed M.A., De Winter C., Verhaaf B., Jankie A., Reuser A.J., Van Den Ouweland A.M., Van Der Sluijs P., and Halley D.J. Identification and characterization of the interaction between tuberin and 14-3-3zeta. J Biol Chem 9 (2002) 9
6. Potter C.J., Pedraza L.G., and Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4 (2002) 658-665
7. Sancak Y., Thoreen C.C., Peterson T.R., Lindquist R.A., Kang S.A., Spooner E., Carr S.A., and Sabatini D.M. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Molecular Cell 25 (2007) 903-915. This paper shows that PRAS40 can compete with Rheb for mTORC1 binding, thereby limiting mTORC1 activation by Rheb.
8. Wang L., Harris T.E., Roth R.A., and Lawrence Jr. J.C. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 282 (2007) 20036-20044. Describes PRAS40 as an Akt-regulated inhibitor of substrate binding to mTORC1.
9. Castro A.F., Rebhun J.F., Clark G.J., and Quilliam L.A. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem 278 (2003) 32493-32496
10. Garami A., Zwartkruis F.J., Nobukuni T., Joaquin M., Roccio M., Stocker H., Kozma S.C., Hafen E., Bos J.L., and Thomas G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11 (2003) 1457-1466
11. Tee A.R., Manning B.D., Roux P.P., Cantley L.C., and Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 13 (2003) 1259-1268
12. Zhang Y., Gao X., Saucedo L.J., Ru B., Edgar B.A., and Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5 (2003) 578-581
13. Oshiro N., Takahashi R., Yoshino K., Tanimura K., Nakashima A., Eguchi S., Miyamoto T., Hara K., Takehana K., Avruch J., et al. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem 282 (2007) 20329-20339
14. Fonseca B.D., Smith E.M., Lee V.H., MacKintosh C., and Proud C.G. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem 282 (2007) 24514-24524
15. Nobukuni T., Joaquin M., Roccio M., Dann S.G., Kim S.Y., Gulati P., Byfield M.P., Backer J.M., Natt F., Bos J.L., et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci U S A 102 (2005) 14238-14243
16. Byfield M.P., Murray J.T., and Backer J.M. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 s6 kinase. J Biol Chem 280 (2005) 33076-33082
17. Gulati P., Gaspers L.D., Dann S.G., Joaquin M., Nobukuni T., Natt F., Kozma S.C., Thomas A.P., and Thomas G. Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. Cell Metab 7 (2008) 456-465. This paper demonstrates amino acid regulation of hVps32 via the induction of calcium flux.
18. Siddhanta U., McIlroy J., Shah A., Zhang Y., and Backer J.M. Distinct roles for the p110alpha and hVPS34 phosphatidylinositol 3′-kinases in vesicular trafficking, regulation of the actin cytoskeleton, and mitogenesis. J Cell Biol 143 (1998) 1647-1659
19. Sancak Y., Peterson T.R., Shaul Y.D., Lindquist R.A., Thoreen C.C., Bar-Peled L., and Sabatini D.M. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320 (2008) 1496-1501. Together with reference [18], this paper establishes the role of Rag proteins in nutrient control of mTORC1.
20. ••], this paper establishes the role of Rag proteins in nutrient control of mTORC1.
21. Long X., Lin Y., Ortiz-Vega S., Busch S., and Avruch J. The Rheb switch 2 segment is critical for signaling to target of rapamycin complex 1. J Biol Chem 282 (2007) 18542-18551
22. Long X., Ortiz-Vega S., Lin Y., and Avruch J. Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J Biol Chem 280 (2005) 23433-23436
23. Edinger A.L., Cinalli R.M., and Thompson C.B. Rab7 prevents growth factor-independent survival by inhibiting cell-autonomous nutrient transporter expression. Dev Cell 5 (2003) 571-582
24. Stein M.P., Feng Y., Cooper K.L., Welford A.M., and Wandinger-Ness A. Human VPS34 and p150 are Rab7 interacting partners. Traffic 4 (2003) 754-771
25. Chiang G.G., and Abraham R.T. Targeting the mTOR signaling network in cancer. Trends Mol Med 13 (2007) 433-442
26. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., and Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22 (2006) 159-168
27. Kim D.H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., Tempst P., and Sabatini D.M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110 (2002) 163-175
28. McMahon L.P., Choi K.M., Lin T.A., Abraham R.T., and Lawrence Jr. J.C. The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin. Mol Cell Biol 22 (2002) 7428-7438
29. Edinger A.L., Linardic C.M., Chiang G.G., Thompson C.B., and Abraham R.T. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res 63 (2003) 8451-8460
30. •]), this paper suggested FKBP38 as a cell-intrinsic analog of rapamycin-FKBP12.
31. Wang X., Fonseca B.D., Tang H., Liu R., Elia A., Clemens M.J., Bommer U.A., and Proud C.G. Re-evaluating the roles of proposed modulators of mammalian target of rapamycin complex 1 (mTORC1) signaling. J Biol Chem 283 (2008) 30482-30492. This paper challenged the roles of FKBP38 and TCTP in mTORC1 regulation.
32. •]) has challenged this model.
33. Rehmann H., Bruning M., Berghaus C., Schwarten M., Kohler K., Stocker H., Stoll R., Zwartkruis F.J., and Wittinghofer A. Biochemical characterisation of TCTP questions its function as a guanine nucleotide exchange factor for Rheb. FEBS Lett 582 (2008) 3005-3010
34. Battaglia M., Stabilini A., and Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105 (2005) 4743-4748
35. Sauer S., Bruno L., Hertweck A., Finlay D., Leleu M., Spivakov M., Knight Z.A., Cobb B.S., Cantrell D., O'Connor E., et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 105 (2008) 7797-7802
36. Marx S.O., Jayaraman T., Go L.O., and Marks A.R. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76 (1995) 412-417
37. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
38. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
39. Kastrati A., Mehilli J., Pache J., Kaiser C., Valgimigli M., Kelbaek H., Menichelli M., Sabate M., Suttorp M.J., Baumgart D., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039. An interesting study linking nutrient-stimulated mTORC1 signaling to rapamycin efficacy in cardiovascular stents.
40. Luo Y., Marx S.O., Kiyokawa H., Koff A., Massague J., and Marks A.R. Rapamycin resistance tied to defective regulation of p27Kip1. Mol Cell Biol 16 (1996) 6744-6751
41. Shan J., Nguyen T.B., Totary-Jain H., Dansky H., Marx S.O., and Marks A.R. Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors. Proc Natl Acad Sci U S A 105 (2008) 19006-19011
42. Inoki K., Corradetti M.N., and Guan K.L. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37 (2005) 19-24
43. Roach E.S., Gomez M.R., and Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 13 (1998) 624-628
44. Crino P.B., Nathanson K.L., and Henske E.P. The tuberous sclerosis complex. N Engl J Med 355 (2006) 1345-1356
45. Harabayashi T., Shinohara N., Katano H., Nonomura K., Shimizu T., and Koyanagi T. Management of renal angiomyolipomas associated with tuberous sclerosis complex. J Urol 171 (2004) 102-105
46. Juvet S.C., McCormack F.X., Kwiatkowski D.J., and Downey G.P. Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol 36 (2007) 398-408
47. Kpodonu J., Massad M.G., Chaer R.A., Caines A., Evans A., Snow N.J., and Geha A.S. The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis. J Heart Lung Transplant 24 (2005) 1247-1253
48. Kwiatkowski D. TSC1, TSC2, TSC3? or mosaicism?. Eur J Hum Genet 13 (2005) 695-696
49. Bissler J.J., McCormack F.X., Young L.R., Elwing J.M., Chuck G., Leonard J.M., Schmithorst V.J., Laor T., Brody A.S., Bean J., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358 (2008) 140-151. An important study demonstrating the therapeutic potential of Rapamycin for AML and LAM.
50. Davies D.M., Johnson S.R., Tattersfield A.E., Kingswood J.C., Cox J.A., McCartney D.L., Doyle T., Elmslie F., Saggar A., de Vries P.J., et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 358 (2008) 200-203
51. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
52. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., Giaccia A.J., and Abraham R.T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22 (2002) 7004-7014
53. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., and Semenza G.L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60 (2000) 1541-1545
54. Cloughesy T.F., Yoshimoto K., Nghiemphu P., Brown K., Dang J., Zhu S., Hsueh T., Chen Y., Wang W., Youngkin D., et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5 (2008) e8
55. Galanis E., Buckner J.C., Maurer M.J., Kreisberg J.I., Ballman K., Boni J., Peralba J.M., Jenkins R.B., Dakhil S.R., Morton R.F., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clinical Oncol 23 (2005) 5294-5304
56. Fan Q.W., Knight Z.A., Goldenberg D.D., Yu W., Mostov K.E., Stokoe D., Shokat K.M., and Weiss W.A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9 (2006) 341-349
57. Kharas M.G., Janes M.R., Scarfone V.M., Lilly M.B., Knight Z.A., Shokat K.M., and Fruman D.A. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 118 (2008) 3038-3050
58. Park S., Chapuis N., Bardet V., Tamburini J., Gallay N., Willems L., Knight Z.A., Shokat K.M., Azar N., Viguie F., et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 22 (2008) 1698-1706
59. Thoreen C.C., Kang S.A., Chang J.W., Liu Q., Zhang J., Gao Y., Reichling L.J., Sim T., and Sabatini D.M. Gray NS: An ATP-competitive mTOR inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284 (2009) 8023-8032
60. Feldman M.E., Apsel B., Uotila A., Loewith, Knight Z.A., Ruggero D., and Shokat KM:. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7 (2009) e1000038
61. Rathmell J.C., Fox C.J., Plas D.R., Hammerman P.S., Cinalli R.M., and Thompson C.B. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 23 (2003) 7315-7328
62. Edinger A.L., and Thompson C.B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 13 (2002) 2276-2288
63. Plas D.R., Talapatra S., Edinger A.L., Rathmell J.C., and Thompson C.B. Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. J Biol Chem 276 (2001) 12041-12048